logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2020 – PFS benefit with second-line pyrotinib+capecitabine for HER2+ metastatic breast cancer

Phase 3 PHOEBE trial verifies clinical value of the new pan-ErbB tyrosine kinase inhibitor pyrotinib.